secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2025-04-24T23:59:59+00:00
Accession:  0001193125-25-091736
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior Q1 net revenue $266M, in line; GAAP EPS $0.38, non-GAAP $0.41; FY guidance unchanged
--------------------------------------------------------------------------------

- Net revenue $266M (-6% YoY), in line with expectations; U.S. net revenue $222M (-8%).
- SUBLOCADE NR $176M (-2% YoY); FY 2025 guidance unchanged at $725M-$765M.
- GAAP diluted EPS $0.38 (down 15%); non-GAAP diluted EPS $0.41 (down 2%).
- SG&A $132M (-8% YoY non-GAAP) reflects cost savings; FY non-GAAP SG&A guided $525M-$535M.
- Revised prior financials to correct Branded Fee accrual (immaterial $6M overstatement in 2024).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000119312525091736/0001193125-25-091736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000119312525091736/d926381d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-091736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer